Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT01909492
What this trial is testing

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Providence Health & Services 30
Not applicableStudy completedNCT03983681
What this trial is testing

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

Who this might be right for
Multiple Sclerosis
Kessler Foundation 81
Post-approval studies (Phase 4)UnknownNCT04048577
What this trial is testing

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Berkovich, Regina MD, PhD Inc. 10
Early research (Phase 1)UnknownNCT00220493
What this trial is testing

Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients

Who this might be right for
Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Chronic Progressive
Sheba Medical Center 80
Testing effectiveness (Phase 2)Study completedNCT00451204
What this trial is testing

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of California, Los Angeles 158
Testing effectiveness (Phase 2)Study completedNCT05168384
What this trial is testing

Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Abu Dhabi Stem Cells Center 15
Large-scale testing (Phase 3)Ended earlyNCT03342638
What this trial is testing

Maximizing Outcome of Multiple Sclerosis Transplantation

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Northwestern University 66
Post-approval studies (Phase 4)WithdrawnNCT02090348
What this trial is testing

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen
Testing effectiveness (Phase 2)UnknownNCT02369926
What this trial is testing

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Transparency Life Sciences 20
Not applicableLooking for participantsNCT07230015
What this trial is testing

Combined Motor Imagery and Vestibular Rehab for MS

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Medipol University 30
Not applicableUnknownNCT00914758
What this trial is testing

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Washington Neuropsychology Research Group 1
Large-scale testing (Phase 3)WithdrawnNCT01975298
What this trial is testing

Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT07189325
What this trial is testing

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Anti-CD20 Therapy
University Hospital, Montpellier 250
Not applicableActive Not RecruitingNCT07757568
What this trial is testing

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

Who this might be right for
Multiple Sclerosis (MS) Relapsing Remitting
University of Colorado, Denver 11
Not applicableNot Yet RecruitingNCT07029867
What this trial is testing

Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapse Remitting Multiple Sclerosis
Ying Gao 152
Post-approval studies (Phase 4)Study completedNCT00168766
What this trial is testing

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Biogen 345
Post-approval studies (Phase 4)Study completedNCT02499900
What this trial is testing

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 861
Not applicableActive Not RecruitingNCT06282081
What this trial is testing

Serum Neurofilament Light in Multiple Sclerosis

Who this might be right for
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Dent Neuroscience Research Center 42
Not applicableStudy completedNCT04832399
What this trial is testing

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 60
Testing effectiveness (Phase 2)Study completedNCT01470521
What this trial is testing

Worms for Immune Regulation of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of Nottingham 72
Next Page